Consistent with its role as an inhibitor of cell survival and growth, DAB2IP expression is often down-regulated in several human cancers [6–9], which is frequently associated with the promoter hypermethylation [8–13] or enhancer of zeste homolog 2 (EZH2)-mediated transcriptional silencing [14, 15]. The gene discussed is EZH2; the disease is cancer.